FINHUB Insights

BSX · Q2 FY26 · Apr 1 – Jun 30, 2026

Boston Scientific Q2 FY26: where the revenue came from and where it went

Boston Scientific Q2 FY26: revenue $5.4B (+8% year over year). Net profit $0.9B. Largest cohort MedSurg $1.7B. The whole income statement as a sankey diagram from the SEC filing.

Period
Apr 1 – Jun 30, 2026
Reported
May 1, 2026 10-Q
Sankey diagram of Boston Scientific's income statement for Q2 FY26: revenue of $5.44 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.44B +8% year over year
Gross profit$3.85B 71% margin
Operating profit$1.18B 22% margin
Net profit$0.91B 17% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
ItemValueShare of revenueYear over year
Revenue 5.44 100% +8%
MedSurg 1.70 31%
Electrophysiology 0.91 17% +8%
Endoscopy 0.74 14% +0%
Urology 0.65 12% −4%
Cardiac rhythm management 0.58 11% −2%
Watchman 0.51 9% +4%
Neuromodulation 0.32 6% +5%
Other 0.05 1%
Cost of revenue−1.5929%
Gross profit3.8571% margin+3pp
SG&A−1.8033%−1pp
Other−0.8716%+0pp
Operating profit1.1822% margin+5pp
Tax−0.16
Interest & other costs−0.12
Net profit0.9117%+1pp
Filing on EDGAR More quarters of BSX

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters